Publication:
Comparison of SARS-CoV-2 antibodies and six immunoassays in pediatric and adult patients 12 weeks after COVID-19

dc.contributor.authorSağlık, Imran
dc.contributor.authorTürkkan, Alparslan
dc.contributor.authorTuran, Cansu
dc.contributor.authorKara, Ateş
dc.contributor.authorAkalın, Halis
dc.contributor.authorEner, Beyza
dc.contributor.authorŞahin, Ahmet
dc.contributor.authorYeşil, Edanur
dc.contributor.authorÇelebi, Solmaz
dc.contributor.authorKazak, Esra
dc.contributor.authorHeper, Yasemin
dc.contributor.authorYılmaz, Emel
dc.contributor.authorKorkmaz, Muhammet Furkan
dc.contributor.authorTüre, Esra
dc.contributor.authorHacımustafaoğlu, Mustafa
dc.contributor.buuauthorSAĞLIK, İMRAN
dc.contributor.buuauthorTürkkan, Alparslan
dc.contributor.buuauthorTURAN, CANSU
dc.contributor.buuauthorAKALIN, EMİN HALİS
dc.contributor.buuauthorENER, BEYZA
dc.contributor.buuauthorÇELEBİ, SOLMAZ
dc.contributor.buuauthorKAZAK, ESRA
dc.contributor.buuauthorHEPER, YASEMİN
dc.contributor.buuauthorYILMAZ, EMEL
dc.contributor.buuauthorHACIMUSTAFAOĞLU, MUSTAFA KEMAL
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Halk Sağlığı Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversite/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.
dc.contributor.researcheridGCM-3391-2022
dc.contributor.researcheridCDH-6078-2022
dc.contributor.researcheridIVB-4013-2023
dc.contributor.researcheridAAU-8952-2020
dc.contributor.researcheridCNK-0895-2022
dc.contributor.researcheridENK-4130-2022
dc.contributor.researcheridAAG-8459-2021
dc.contributor.researcheridCTY-9474-2022
dc.contributor.researcheridGDP-0005-2022
dc.contributor.researcheridCTG-5805-2022
dc.date.accessioned2024-11-29T13:11:45Z
dc.date.available2024-11-29T13:11:45Z
dc.date.issued2022-02-14
dc.description.abstractIntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients' characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens.MethodsThis prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies.ResultsThe findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001).ConclusionOverall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity ( 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies.
dc.identifier.doi10.7759/cureus.22195
dc.identifier.issue2
dc.identifier.urihttps://doi.org/10.7759/cureus.22195
dc.identifier.urihttps://www.cureus.com/articles/86024-comparison-of-sars-cov-2-antibodies-and-six-immunoassays-in-pediatric-and-adult-patients-12-weeks-after-covid-19#!/
dc.identifier.urihttps://hdl.handle.net/11452/48728
dc.identifier.volume14
dc.identifier.wos000757951000011
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherSpringernature
dc.relation.journalCureus Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntibody persistence
dc.subjectAdult
dc.subjectPediatric
dc.subjectSars-cov-2
dc.subjectSerological assay
dc.subjectCovid-19
dc.subjectGeneral & internal medicine
dc.titleComparison of SARS-CoV-2 antibodies and six immunoassays in pediatric and adult patients 12 weeks after COVID-19
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationaab7d5dd-72a4-4f3a-a677-1fdf3e13cadc
relation.isAuthorOfPublication92778d28-f35c-48cf-ae86-8046442203bb
relation.isAuthorOfPublication4fb46529-3295-4383-97b1-7c494ff32c24
relation.isAuthorOfPublication2b082cc1-092b-441d-bafb-e08676bd66bb
relation.isAuthorOfPublication28076e30-7802-4de2-ae05-028643d56968
relation.isAuthorOfPublication44aa832e-512b-446e-b095-bd59406744bd
relation.isAuthorOfPublicationa50debc9-b02f-4f87-aba0-567e0af2063e
relation.isAuthorOfPublication149687a4-4cd9-46c4-8b3a-8cbdec8ac7e9
relation.isAuthorOfPublication0f1ad7e3-4cce-40b2-bbb3-7200fae5f769
relation.isAuthorOfPublication.latestForDiscoveryaab7d5dd-72a4-4f3a-a677-1fdf3e13cadc

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Turkkan_vd_2022.pdf
Size:
169.98 KB
Format:
Adobe Portable Document Format

Collections